Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06432465 · ClinicalTrials.gov registry record · NA
tDCS to Decrease Opioid Relapse (UH3)
A NA study of Opioid Use Disorder, sponsored by Butler Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06432465: Recruiting NA study of Opioid Use Disorder, sponsored by Butler Hospital.
NCT06432465 is a NA study of Opioid Use Disorder that is actively recruiting participants, run by Butler Hospital. The registered enrollment target is 100 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06432465, a NA study of Opioid Use Disorder, is actively recruiting participants, sponsored by Butler Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the left DLPFC) delivered during cognitive control network (CCN) priming. In Phase I, the EEG provided validation of expected changes in these networks following tDCS stimulation of the DLPFC. In this current phase (II), the investigators will perform a larger randomized clinical trial (RCT) (active vs. sham control) to address long-term neurobehavioral outcomes, including opioid relapse, craving, and sustained EEG changes.
Primary Outcome
Modified Penn Alcohol Craving (0 = no craving to 30 = extreme craving)
Conditions Studied
Interventions
- DEVICE sham tDCS
- DEVICE active tDCS
Study Locations (1)
Rhode Island
- Butler Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-04-17 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT06432465 shows while recruiting
NCT06432465 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which sham tDCS is the first listed.
NCT06432465 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT06432465 about?
NCT06432465 is a clinical study titled "tDCS to Decrease Opioid Relapse (UH3)". Investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the left DLPFC) delivered during cognitive control network (CCN) priming. In Phase I, the EEG provided va...
What is the current status of trial NCT06432465?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2024-04-17. Estimated completion is 2026-12-31.
What conditions does trial NCT06432465 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT06432465?
The interventions under investigation include: sham tDCS (DEVICE), active tDCS (DEVICE).
Who is sponsoring clinical trial NCT06432465?
This trial is sponsored by Butler Hospital, which has 103 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06432465 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06432465's enrollment target sits among peer trials
100 130th of 257 higher than 121 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
RECRUITING · NA
-
Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD
RECRUITING · NA
-
Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail
RECRUITING · NA
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
Using Facebook to Support Opioid Recovery Among American Indian Women
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01773278 · 100 participants · Phase 2
Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI